Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00398515 | Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00547365 | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | completed | Phase 1 / Phase 2 | 10 | University of TennesseeOTHER | 1 | Sep 19, 2013 | clinicaltrials |
| NCT01232712 | A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies | completed | Phase 1 / Phase 2 | 15 | Vaxil Therapeutics Ltd.INDUSTRY | 1 | Aug 9, 2013 | clinicaltrials |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | completed | Phase 1 | 39 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients(EVOLUTION) | completed | Phase 1 / Phase 2 | 158 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00723359 | Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT01371227 | A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | terminated | Phase 1 | 9 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT01149668 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | completed | Phase 1 | 7 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01695590 | Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Prolexys PharmaceuticalsINDUSTRY | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00346255 | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma(IMGN901) | completed | Phase 1 | 37 | ImmunoGen, Inc.INDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT01686386 | Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 60 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Feb 20, 2013 | clinicaltrials |
| NCT01074060 | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00428545 | Bevacizumab and Bortezomib in Patients With Advanced Malignancy | completed | Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00310024 | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00062621 | Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure | completed | Phase 1 | 5 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00028821 | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00003166 | Bryostatin and Vincristine in B-Cell Malignancies | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00124605 | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | unknown | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00882063 | Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Piramal Enterprises LimitedINDUSTRY | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00920855 | Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | CephalonINDUSTRY | 1 | Oct 4, 2012 | clinicaltrials |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | terminated | Phase 1 / Phase 2 | 39 | Emory UniversityOTHER | 1 | Aug 30, 2012 | clinicaltrials |
| NCT00303199 | Study of ZIO-101 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Alaunos TherapeuticsINDUSTRY | 2 | Jul 19, 2012 | clinicaltrials |
| NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | completed | Phase 1 | 12 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00415064 | Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma | completed | Phase 1 | 32 | AEterna ZentarisINDUSTRY | 1 | Jul 6, 2012 | clinicaltrials |
| NCT00660166 | Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | completed | Phase 1 | 13 | Tufts Medical CenterOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT01010243 | Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial(MM03) | unknown | Phase 1 / Phase 2 | 54 | University of RegensburgOTHER | 1 | May 30, 2012 | clinicaltrials |
| NCT00234169 | A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 10, 2012 | clinicaltrials |
| NCT00089453 | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | completed | Phase 1 | 10 | University of ArkansasOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 23, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Nov 11, 2013source: clinicaltrials